Back to top
more

Baxter International (BAX)

(Delayed Data from NYSE)

$35.87 USD

35.87
3,167,156

+0.17 (0.48%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $35.75 -0.12 (-0.33%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Henry Schein (HSIC) Q2 Earnings Beat Estimates, Revenues Miss

Henry Schein (HSIC) sees solid performance by the global Medical and Technology and Value-added Services businesses in Q2.

Becton, Dickinson (BDX) Beats on Q3 Earnings and Revenues

Strong contributions from BD Medical and Interventional units drive Becton, Dickinson???s (BDX) fiscal third quarter.

Hill-Rom (HRC) Beats on Q3 Earnings, Tightens '19 Guidance

Hill-Rom (HRC) registers a solid year-over-year increase in revenues on robust domestic growth.

Integer Holdings (ITGR) Q2 Earnings Beat, Revenues Miss

Higher revenues and strong 2019 outlook benefit Integer Holdings' (ITGR) Q2 earnings.

HMS Holdings (HMSY) Q2 Earnings and Revenues Top Estimates

Higher revenues, gross margin expansion and raised 2019 outlook benefit HMS Holdings' (HMSY) Q2 earnings.

Intersect (XENT) Q2 Loss Wider Than Estimates, Revenues Miss

Intersect ENT's (XENT) lowered revenue guidance for 2019 raises concern.

PRA Health (PRAH) Q2 Earnings Beat, EPS Guidance Narrowed

PRA Health (PRAH) slashes 2019 revenue guidance; direct costs surge in second quarter.

Teleflex (TFX) Q2 Earnings Top Estimates, Margins Improve

Teleflex (TFX) sees robust revenue improvement across majority of segments and all geographies.

Teleflex (TFX) Q2 Earnings Top Estimates, Margins Improve

Teleflex (TFX) sees robust revenue improvement across majority of segments and all geographies.

Globus Medical (GMED) Q2 Earnings In Line, Revenue View Up

Globus Medical's (GMED) spine business gains traction from solid worldwide growth in the second quarter.

Genomic Health (GHDX) to Join Exact Sciences, Posts Q2 Results

The merger of Genomic Health (GHDX) with Exact Sciences will combine two of the strongest brands in cancer diagnostics, Cologuard and OncotypeDX, providing platform for growth.

DexCom (DXCM) Q2 Earnings and Revenues Surpass Estimates

Higher revenues, solid performing Sensor and Transmitter segments and strong 2019 outlook benefit DexCom's (DXCM) Q2 earnings. However, contraction in gross margin remains a woe.

Bio-Rad (Bio) Q2 Earnings Beat Estimates, Margins Expand

We are upbeat about Bio-Rad's (BIO) year-over-year revenue growth within the Clinical Diagnostics segment in Q2.

DENTSPLY SIRONA (XRAY) Q2 Earnings Beat, Revenues Fall Y/Y

DENTSPLY SIRONA (XRAY) raises guidance for 2019 adjusted EPS.

DaVita (DVA) Earnings Beat, Revenues Miss Estimates in Q2

DaVita (DVA) completes divestment of DMG unit to Optum for $4.34 billion.

Bruker (BRKR) Q2 Earnings Beat Estimates, Margins Expand

Bruker (BRKR) registers strong year-over-year revenue growth across all segments and geographies.

Amedisys (AMED) Q2 Earnings Top Estimates, Margins Decline

Robust year-over-year growth in Medicare and non-Medicare revenues aids Amedisys' (AMED) Home Health and Hospice divisions.

Hologic (HOLX) Beats on Q3 Earnings, Ups '19 Revenue View

Hologic's (HOLX) strong top-line growth in Q3 is led by a solid year-over-year rise in core businesses like Breast Health and Molecular Diagnostics.

McKesson (MCK) Q1 Earnings and Revenues Surpass Estimates

McKesson's (MCK) Q1 results benefit from higher revenues and solid show by U.S. Pharmaceutical and Specialty, and Medical-Surgical Solutions.

AmerisourceBergen (ABC) Q3 Earnings & Revenues Top Estimates

Higher revenues, segmental growth and raised 2019 EPS outlook benefit AmerisourceBergen's (ABC) Q3 earnings.

Luminex (LMNX) Reports Q2 Loss, Beats Revenue Estimates

Higher revenues and solid performance across System Sales, Consumable Sales and Royalty Revenues benefit Luminex's (LMNX) Q2 earnings. However, gross margin contraction remains a woe.

CONMED (CNMD) Q2 Earnings and Revenues Surpass Estimates

Higher revenues, solid segmental performance and strong adjusted gross margins benefit CONMED's (CNMD) Q2 earnings. However, high long-term debt remains a concern.

ABIOMED (ABMD) Q1 Earnings Top Estimates, Sales Rise in Japan

ABIOMED (ABMD) slashes revenue guidance for fiscal 2020.

IDEXX (IDXX) Beats Q2 Earnings Estimates, Lifts EPS Guidance

IDEXX's (IDXX) top line in the second quarter gains from strong sales at the CAG business.

Surmodics (SRDX) Q3 Earnings Beat Estimates, Guidance Raised

Surmodics (SRDX) continues to gain from core Medical Devices unit, which saw significant contribution from the SurVeil deal with Abbott in Q3.